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Balance between oxidants  
and antioxidants in human diseases
Oxidative mechanisms play a key role in the 
pathogenesis of virtually all human diseases, and 
consequently antioxidants share a broad range of 
protective effects. It should be made clear that, like 
the exposure to oxidants just increases the risk of 
contracting a given disease, generally in association 
with other pathogenetic determinants, antioxidants 
alone are not likely to fully prevent a pathological 
condition but are just expected to contribute to lower its 
risk and to attenuate the severity of its consequences. 
Together with deprivation of antioxidant mechanisms, 
oxidative stress is also involved in the aging 
process, especially when causing mutations in the 
mitochondrial DNA.
Free radicals include reactive oxygen species (ROS), 
such as the superoxide anion (O2–) and the hydroxyl 
radical (•OH), an extremely reactive species, as well 
as ‘non-radical reactive molecules’, such as hydrogen 
peroxide (H2O2), and reactive nitrogen species (RNS), 
such as peroxynitrite (ONOO−). These species cause 
redox-modulated signaling cascades involving the 
transcription factors AP-1 (activator protein-1), NF-
κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) and/or Nrf2 (nuclear factor erythroid 
2–related factor 2), which can mediate a variety 
either of physiological functions or alterations of 
macromolecules leading to pathological conditions [1]. 
Free radicals may either be introduced into the body 
from exogenous sources (for instance, smoking one 
cigarette produces 1016 radicals)  [2] or be generated 
in the body via biochemical reactions, such as the 
Fenton reaction and the Haber-Weiss reaction. While a 
controlled production of reactive molecules is essential 
for normal physiological and cellular functions, 
their uncontrolled or excessive production can cause 
‘oxidative/nitrosative stress’ [1].
Natural or synthetic antioxidants have the capability 
to counteract the actions of oxidants either by directly 
scavenging ROS or by inhibiting oxidant generating 
enzymes, e.g. xanthine oxidase, or by stimulating ROS 
metabolizing enzymes, such as catalase, superoxide 
dismutase, or glutathione peroxidase, or by regulating 
the aforementioned redox-sensitive transcription 
factors. Therefore, in principle, agents possessing 
antioxidant properties can prevent the generation of 
ROS and hamper their deleterious effects. However, an 
indiscriminate use of antioxidants should be avoided 
because under certain conditions and at certain doses 
some of them may become pro-oxidants [1]. A typical 
example is provided by ascorbic acid that, at high doses 
and in the presence of transition metal ions, such as 
iron and copper, can acquire pro-oxidative properties, 
in spite of the fact that the interaction between ascorbic 
acid and iron is of nutritional, physiological, and 
pharmacological interest [3].
Oxidative mechanisms are not only involved in chronic degener-
ative diseases but also in infectious diseases, among which viral 
respiratory diseases. Antioxidants have the capability to coun-
teract the action of oxidants by scavenging reactive oxygen spe-
cies (ROS) and by inhibiting oxidant generating enzymes. Over-
production of ROS and deprivation of antioxidant systems play a 
major role in COVID-19 occurrence, progression, and severity. 
Interconnected pathways account for the relationships between 
oxidative damage and inflammation resulting from an inter-
play between transcription factors having opposite effects. For 
instance, Nrf2 downregulates inflammation by inhibiting endog-
enous antioxidant enzymes such as NQO-1 and HO-1. On the 
other hand, NF-κB upregulates pro-inflammatory cytokines and 
chemokines, such as IL-1β, IL-6, IL-8, PGE-2, COX-2, TNF-α, 
MMP-3, and MMP-4. A central protective role against oxidants 
is played by reduced glutathione (GSH), which is depleted in 
SARS-CoV-2 infection. N-acetylcysteine (NAC), a precursor of 
GSH, is of particular interest as an anti-COVID-19 agent. GSH 
and NAC hamper binding of the S1 subunit of SARS-CoV-2 spike 
proteins to the angiotensin-converting enzyme 2 (ACE2) recep-
tor. In addition, NAC and its derivatives possess a broad array 
of antioxidant and antiinflammatory mechanisms that could be 
exploited for COVID-19 prevention and adjuvant therapy. In 
particular, as demonstrated in a previous clinical trial evaluat-
ing influenza and influenza-like illnesses, the oral administra-
tion of NAC may be expected to decrease the risk of developing 
COVID-19. Furthermore, at the very high doses used worldwide 
as an antidote against paracetamol intoxication, intravenous 
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Involvement of oxidative stress 
in respiratory viral diseases  
and protection by antioxidants 
Oxidative stress is strongly involved in the pathogenesis 
not only of chronic degenerative diseases, such as 
cancer, atherosclerosis, arterial hypertension and 
other cardiovascular diseases, neurological disorders, 
dysmetabolic conditions such as diabetes mellitus, 
rheumatoid arthritis, etc.  [4], but also of infectious 
diseases. Respiratory viral diseases are often associated 
with cytokine production, inflammation, and other 
pathophysiological processes resulting from a redox 
imbalance, disruption of the thiol redox cycle and 
other redox circuits  [5]. Thus, overproduction of ROS 
and antioxidant mechanisms deprivation are one of the 
key events that is linked to viral replication and the 
subsequent virus-associated disease [6].
Respiratory viruses cause infections of the upper or lower 
respiratory tract that affect every year millions of people. 
They include influenza viruses (Orthomyxoviridae 
family), human respiratory syncytial viruses (HRSV, 
Pneumoviridae family), human rhinoviruses (HRV, 
Picornaviridae family), human metapneumoviruses 
(HMPV) and parainfluenza viruses (both belonging to the 
Paramyxoviridae family), adenoviruses (Adenoviridae 
family), and coronaviruses (Coronaviridae family). With 
the exception of adenoviruses, having a DNA genome, 
all the other respiratory viruses are RNA viruses. 
Many lines of evidence suggest that marked signs of 
increased production of ROS accompany all respiratory 
viral infections, along with disturbance of antioxidant 
defences [6]. The sources of ROS in airway epithelial cells 
infected with viruses are mainly NADPH oxidases, dual 
oxidase, xanthine oxidase, and Nox2 (NADPH oxidase), 
which is mainly expressed in macrophages. Alterations 
of ROS-producing and scavenging pathways that are 
caused by respiratory viral infections are implicated in 
inflammation, lung epithelial disruption, tissue damage, 
and cell death resulting in macrophage activation. In 
addition, oxidative stress triggers an antiviral immune 
response, whose excess may lead to a cytokine storm 
and a severe inflammation  [5]. Respiratory viral 
infections have been associated with inhibition of Nrf2 
pathways and/or NF-kB signaling activation, leading to 
inflammation and oxidative damage [7].
The role of oxidative mechanisms is also supported by 
experimental and clinical findings that show protective 
effects of antioxidants such as vitamin C, vitamin E, 
and N-acetylcysteine (NAC). NAC is the only agent 
that has been shown to attenuate the risk of respiratory 
viral diseases in humans. In particular, a double-
blind trial involved 262  subjects of both genders who 
were enrolled in 20  Italian Centres. These subjects 
were randomized to receive either placebo or NAC 
tablets (600 mg) twice daily for 6 months. The results 
demonstrated that administration of NAC during the 
cold season can attenuate the incidence and severity of 
influenza and influenza-like illnesses, as shown by the 
fact that both local and systemic symptoms were sharply 
and significantly reduced in the NAC group. Moreover, 
only 25% of A/H1N1 influenza virus-infected subjects 
receiving NAC developed a symptomatic form versus 
79% in the placebo group  [8]. In the same study, a 
time-related shift of anergic condition to normoergic 
condition was observed in the NAC group thereby 
showing a beneficial effect of NAC administration on 
cell-mediated immunity [8].
The protective effects of NAC towards respiratory viral 
diseases have also been confirmed and explored from a 
mechanistic point of view in experimental test systems. 
Influenza A and B viruses and HRSV are responsible 
for COPD (chronic obstructive pulmonary diseases) by 
increasing apoptosis and inflammatory events through 
mechanisms that involve ROS generation and release 
of mucins from epithelial cells. NAC inhibited the 
replication of influenza A and B viruses and HRSV and 
restored the normal functions of alveolar type II A549 
cells by modulating MUC5AC overexpression and 
release and by inhibiting IL-8, IL-6 and TNF- α as well as 
NF-κB translocation to the nucleus and phosphorylation 
of MAPK p38  [9]. In addition, NAC inhibited virus 
replication and expression of pro-inflammatory 
molecules in the same cells infected with the highly 
pathogenic H5N1 influenza virus  [10]. In vivo, NAC 
attenuated the pulmonary inflammation and oedema 
and decreased myeloperoxidase activity, neutrophils, 
macrophages, TNF-α, IL-6, IL-1β and chemokine 
ligand-10 in the bronchoalveolar lavage fluid of mice 
inoculated intranasally with A/swine/HeBei/012/2008/ 
H9N2 influenza virus  [11]. Interestingly, in the 
perspective of using NAC for COVID-19 treatment in 
association with antivirals, NAC exerted protective 
effects towards influenza viruses when administered in 
association with either ribavirin [12] or oseltamivir [13].
Oxidative mechanisms in COVID-19 
pathogenesis
The clinical patterns in most SARS-CoV-2-infected 
subjects are similar to those of other respiratory diseases. 
The forms are often paucisymptomatic or even evolve 
as an asymptomatic infection. However, approximately 
15% of COVID-19 patients suffer from impairment of 
gas exchange and pneumonia, and 5% undergo acute 
respiratory distress syndrome (ARDS), the leading cause 
of death in COVID-19 patients, and can experience 
septic shock and/or multiple organ failure that require 
hospitalization in intensive care units (ICU) [14]. ARDS 
involves a systemic inflammatory response that has 
been attributed to the release of mediators triggering an 
attack by the immune system [15]. Like other viruses, 
SARS-CoV-2 stimulates the massive production of 
proinflammatory cytokines and chemokines, such 
as TNFα, IL6, and IL8, referred to as “cytokine 
storm”, which is responsible for lung tissue damage 
and causes cell death  [5]. Although SARS-CoV-2 
primarily replicates in the respiratory tract, autopsies 
demonstrate that this virus can infect cells in multiple 
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organs, including the lungs, pharynx, heart, liver, brain, 
and kidneys  [16]. Cardiovascular alterations include a 
plethora of disorders, such as stroke, diffuse thrombosis, 
acute changes in myocardial demand and supply due to 
tachycardia, hypotension, hypoxemia resulting in type 
2 myocardial infarction, acute coronary syndrome due 
to acute atherothrombosis, microvascular dysfunction 
due to diffuse microthrombi or vascular injury, stress-
related cardiomyopathy (Takotsubo syndrome), direct 
viral cardiomyocyte toxicity, and myocarditis  [17]. 
Moreover, some COVID-19 patients exhibit widespread 
neurological manifestations including acute ischemic 
stroke, intracerebral haemorrhage, cerebral venous 
sinus thrombosis and anosmia. COVID-19-associated 
coagulopathy is increasingly recognized as a result of 
acute infection and is likely caused by the inflammatory 
cytokine storm [18].
Similarly to influenza virus infection, infection of 
experimental animals with coronaviruses has provided 
evidence for the involvement of the oxidative stress 
machinery, with enhancement of ROS production and 
weakening of defence mechanisms  [19]. Many lines 
of evidence suggest that overproduction of ROS and a 
deprivation of antioxidant system play a major role also 
in the pathogenesis of SARS-CoV and SARS-CoV-2 
infections in humans as well as in the progression and 
severity of the related diseases [4]. Activated neutrophils 
and mononuclear phagocytic cells are to a large extent 
responsible for the massive release of ROS into the lung 
tissue [20]. In addition, the massive TNF-α release during 
the cytokine storm could exacerbate ROS production 
via a positive feedback loop by activating NADPH 
oxidases  [21], and TNF-α induced ROS production 
could contribute to the extension of COVID-19 effects 
to distant tissues [2].
The importance of oxidative stress in COVID-19 is also 
reinforced by the role of ROS production in associated 
co-morbidities. Many studies highlighted the importance 
of redox-sensitive pathways as novel cell-based targets 
for therapies aimed at blocking both viral replication and 
virus-induced inflammation  [23]. As discussed in the 
next session, the prominent role of oxidative mechanisms 
in the pathogenesis of COVID-19 is corroborated by the 
perspective of implementing antioxidative strategies in 
the prevention and therapy of COVID-19 [24].
Some antioxidants proposed for COVID-19 
prevention and treatment
Several agents endowed with antioxidant properties have 
been assayed or proposed with the goals of lowering 
the risk of being affected by SARS-CoV-2 infection 
and/or of being used as an adjunct treatment in case of 
severe COVID-19 forms [25]. Often, these compounds 
share multiple mechanisms, which may render them 
capable of exerting broad-spectrum protective effects. 
On the other hand, antioxidants working with different 
mechanisms of action may complement each other 
thereby enhancing their protective properties in a 
synergistic fashion. Most antioxidant compounds are 
molecules from natural sources and especially of dietary 
origin [26], a poor nutrient status being associated with 
oxidative stress, inflammation, and impairment of the 
immune system  [27,  28]. Therefore, a balanced diet 
and supplementation with proper nutrients may play a 
vital role in prevention, treatment, and management of 
COVID-19 [29].
The scientific literature in this area of research is evolving 
very rapidly. Some examples of protective antioxidants 
are shown in Figure  1. Among phytochemicals, 
polyphenols have been shown both in silico and in vitro 
to interfere with various stages of coronavirus entry 
into cells and replication  [30] and disclose inhibitory 
activities towards viral components, which may render 
them potentially suitable to counteract the SARS-
CoV-2 infection  [31]. For instance, flavonoids, which 
are a class of polyphenols including quercetin (Fig. 1), 
baicalin, luteolin, hesperetin, gallocatechin gallate, 
epigallocatechin gallate (EGCG,), etc., are able to 
inhibit key proteins involved in the coronavirus infective 
cycle, such as PLpro, 3CLpro, and NTPase/helicase [30]. 
It has also been postulated that quercetin may exert a 
synergistic antiviral action with vitamin C due to the 
overlapping antiviral and immunomodulatory properties 
of these agents and to the capacity of ascorbate to 
recycle quercetin  [32]. In molecular simulations, 
quercetin has been hypothesized to inhibit the protease 
3CLpro, which is an essential player in the coronavirus 
replication cycle  [33]. It is noteworthy, however, that 
the U.S. Food and Drug Administration has cautioned 
against advertisement of unauthorized health claims of 
quercetin.
In theory, vitamin C (ascorbic acid) may represent a 
suitable tool against SARS-CoV-2 infection because this 
vitamin is a reducing agent and antioxidant acting by 
electron transfer reactions and therefore it reacts with 
ROS such as •OH. However, the appropriateness of its 
use in COVID-19 is still uncertain  [34] also because 
the use of vitamin C in ARDS or sepsis is still a matter 
of debate  [35]. A multicentre prospective randomised 
placebo-controlled trial has been recently designed in 
order to evaluate the effects of high dose intravenous 
vitamin C in COVID-19 patients hospitalized in 
ICUs [36].
A promising agent for the treatment of viral diseases, 
including COVID-19, is melatonin, a potent 
multifunctional signalling hormone secreted by the pineal 
gland that acts as an antioxidant with immunomodulatory 
and anti-inflammatory properties  [37]. Melatonin 
can reduce oxidative stress and efficiently combat the 
cytokine storm and sepsis. In addition, melatonin is 
an inhibitor of calmodulin, an essential intracellular 
component to maintain angiotensin-converting enzyme 2 
(ACE-2) on the cell surface  [38]. Melatonin has been 
proposed in subjects with obesity and diabetes, who 
may undergo severe inflammation and oxidative stress 
following infection with SARS-CoV-2 infection  [39]. 
It has also hypothesized that children do not suffer 
from COVID-19 as much as their grandparents because 
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they have lower levels of melatonin, which is lost with 
age [40]. A clinical trial with an injectable formulation 
of melatonin for intravenous perfusion in ICU patients 
suffering from COVID-19 has been designed [41].
Drugs that are being tested for the treatment of COVID-19 
may also possess antioxidant properties. For instance, 
hydroxychloroquine, an old medication for malaria 
that is also used to treat autoimmune disorders such as 
rheumatoid arthritis and systemic lupus erythematosus, 
shares a number of protective effects, also including 
antioxidant mechanisms  [42]. Note however that, on 
the contrary, the same drug has also been reported to 
have oxidative properties due to a decrease of GSH 
levels [43].
A Chinese medicinal formula consisting of 21  herbs 
(QFPDT) has been recommended in the 6th and 7th 
versions of Clinical Practice Guideline on COVID-19 
in China due to its antioxidant, immunomodulatory and 
antiviral mechanisms [44].
Nrf2 activators are a broad category of antioxidant 
agents that could potentially inhibit SARS-CoV-2. In 
fact, Nrf2 is a transcription factor that regulates the 
expression of antioxidant cytoprotective enzymes via 
a promoter sequence known as antioxidant response 
element (ARE). Regulation of the redox state by Nrf2 
results in the modulation of genes involved in immunity 
and inflammation, also including antiviral mechanisms. 
Nrf-2 activators include a variety of food-derived 
compounds that have extensively been investigated for 
their protective properties, such as curcumin, capsaicin, 
gingerol, EGCG, genistein, the carotenoid lycopene, 
resveratrol, caffeic acid phenethyl ester, diallyl sulphide, 
indole-3-carbinol, and sulphoraphane. Moreover, 
using primary human pulmonary artery endothelial 
cells, the synthetic Nrf2 activator PB125® was found 
to downregulate 36 genes encoding cytokines, such as 
IL-1-beta, IL-6, TNF-α, the cell adhesion molecules 
ICAM-1, VCAM-1, and E-selectin, as well as a group of 
IFN-γ-induced genes, many of which have specifically 
been identified in the cytokine storm observed in fatal 
cases of COVID-19 [45]. 
Among natural Nrf-2 activators, it has been hypothesized 
that, in the light of its low toxicity and of its antioxidant, 
anti-inflammatory, and antiviral activity, curcumin 
may be used as a therapeutic drug for viral pneumonia 
and ALI (acute lung injury)/ARDS. Curcumin exerts 
protective effects by regulating the expression of both 
pro- and anti-inflammatory factors such as IL-6, IL-
8, IL-10, and COX-2, by promoting the apoptosis 
of polymorphonucleate cells, and by scavenging the 
ROS that exacerbate the inflammatory response  [46]. 
EGCG, the most abundant ingredient in green tea leaves 
and a well-known antioxidant, has been proposed as a 
supplementation therapy in COVID-19 patients. Besides 
some antiviral and anti-sepsis actions, the major EGCG 
benefits lie in its anti-fibrotic effect and in the ability 
to downregulate expression and signaling of many 
inflammatory mediators  [47]. Flavonoid supplements, 
combined with vitamin D3, are expected to activate 
Nrf2, which may be a potential target to prevent and/
or decrease SARS-CoV-2 infection severity, reducing 
oxidative stress and inflammation, enhancing innate 
immunity, and downregulating ACE2 receptors [48]. As 
it will be specifically discussed in more detail below, 
the thiols GSH and NAC are additional activators of 
Nrf2 [49].
Selenium (Se) is another important antioxidant whose 
deficiency is likely to play a role in affecting SARS-
CoV-2 virulence and COVID-19 severity. A positive 
association has been reported between COVID-19 rates 
Fig. 1. Some agents endowed with antioxidant properties that have been shown or suspected to play a role in COVID-19 prevention and/
or adjuvant therapy. The quercetin formula is shown as an example of flavonoids and curcumin is shown as an example of Nrf2 activators.
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and previously measured population Se status in 17 cities 
across China [50], and Se deficiency has been associated 
with an increased mortality risk from COVID-19 [51]. 
Se is a component of glutathione peroxidase 1 (GPx1), a 
cytosolic selenoenzyme with known antiviral properties 
(see below), and the interaction between the GPx1 
detoxifying system and the main protease (Mpro) of 
SARS-CoV-2 represents a novel molecular target for 
COVID-19  [52]. Low Se status is a common finding 
in conditions considered at risk for severe COVID-19, 
especially in the elderly, and Se might be beneficial via 
restoration of the host antioxidant capacity, reduction 
of apoptosis and endothelial cell damages as well as 
platelet aggregation  [53]. As inferred from an online 
search for articles published in the period 2010-2020, 
the direct evidence that the micronutrients zinc, Se, 
and vitamin D might be involved in the course and 
outcome of the COVID-19 disease was evaluated to be 
observational and weak. However, based on experiences 
from treatments of SARS and other viral infections, it 
was postulated that nutritive supplements administered 
at an early stage of the infection would be important 
in order to enhance the host resistance against RNA 
viral infections, which might also include severe 
COVID-19  [54]. Another Se compound of interest 
is ebselen, an organoselenium compound exhibiting 
hydroperoxide- and peroxynitrite-reducing activity that 
behaves as a GPx and peroxiredoxin enzyme mimetic. 
Ebselen reacts with a multitude of protein thiols, forming 
a selenosulfide bond, which results in pleiotropic effects 
of antiviral, antibacterial and anti-inflammatory nature 
that may potentially be beneficial in COVID-19 [55]. 
The glutathione (GSH) system
Reduced glutathione (GSH, γ-glutamylcysteinylglycine) 
provides key protective effects against toxic substances 
and infectious agents. GSH is available at micromolar 
concentrations in biological fluids and at millimolar 
concentrations in cells within the endoplasmic reticulum, 
mitochondria and nucleus. The thiol redox circuit 
involves interconversions between GSH and glutathione 
disulfide (GSSG), which are in an approximately 100:1 
ratio inside cells. As shown in Figure 2, GSH is oxidized 
to GSSG via the enzyme glutathione peroxidase (GPx), 
whereas GSSG is reduced to GSH via glutathione 
reductase (GR). The main enzyme involved in GSH 
synthesis is glutamate cysteine ligase (GCL). Besides 
being a potent antioxidant, GSH is a nucleophile that can 
block reactive molecules either per se or via glutathione-
S-transferases (GST)-catalyzed conjugation. 
Literature data support the concept that an endogenous 
deficiency in GSH may underlie the serious manifestations 
and death due to COVID-19 [56]. A common denominator 
in all conditions associated with COVID-19 appears to 
be the impaired redox homeostasis responsible for ROS 
accumulation. Therefore, GSH levels could be critical 
in extinguishing the exacerbated inflammation that 
triggers organ failure in COVID-19  [57]. In addition, 
GSH plays a central role in the pathophysiology of most 
human diseases [58], including those that occur as co-
morbidities with COVID-19.
It is noteworthy that GR was found to be significantly 
increased in the blood serum of COVID-19 patients, 
especially when admitted to ICUs [59]. This alteration 
reflects an oxidative stress imbalance, being an attempt 
to replenish the GSH stores that are depleted by the 
infection. GPx, the other enzyme of the glutathione 
circuit, belongs to a family of antioxidant selenoenzymes 
that functionally link selenium and glutathione, both 
of them showing correlations with clinical outcomes 
in COVID-19  [60]. Cytosolic GPx1 has been shown 
to interact with an inactive C145A mutant of Mpro, the 
main cysteine protease of SARS-CoV-2, but not with 
catalytically active wild-type Mpro. In addition, Mpro 
may be targeting not only GPx1 but also several other 
selenoproteins as well as GCL, the rate-limiting enzyme 
for glutathione synthesis [60]. Thus, Mpro is a potential 
drug target, and a screen with over 10,000 compounds 
identified ebselen as a particularly promising inhibitor 
of this protease [55].
Liposomal GSH has been proposed as an adjunctive 
treatment in COVID-19 patients [61]. Moreover, a case 
report study showed that the repeated use of both oral 
administration and intravenous injection of GSH was 
effective in relieving the severe respiratory symptoms of 
COVID-19, suggesting for the first time the efficacy of 
this antioxidant therapy for COVID-19 [62].
Inhibition of ACE2 by antioxidant thiols
The S1 subunit of SARS-CoV-2 spike proteins binds to 
the angiotensin-converting enzyme 2 (ACE2) receptor 
thereby starting the virus replication cycle in cells. Both 
the receptor binding domain of the viral spike proteins 
and ACE2 have several cysteine residues, and the 
binding affinity is decreased when the disulfide bonds 
of ACE2 and SARS-CoV-2 spike proteins are reduced to 
sulfhydryl groups. Therefore, the redox environment of 
cell surface receptors is regulated by the thiol–disulfide 
Fig. 2. Schematic representation of the glutathione cycle and 
ability of thiols to scavenge ROS. Abbreviations: GSH, reduced 
glutathione; GSSG, oxidized glutathione; GR, glutathione reduc-
tase; GPx, glutathione peroxidase; GLC, glutamate cysteine ligase; 




equilibrium in the extracellular region [63]. ACE2, which 
is expressed in epithelial, endothelial and myocardial 
cells as well as in T lymphocytes, macrophages, and 
hepatocytes  [64], is a protease that is involved in the 
renin/angiotensin system together with the angiotensin-
converting enzyme (ACE), which has opposite effects. In 
fact, while ACE causes vasoconstriction, inflammation, 
apoptosis and oxidative stress due to the production 
of ROS through the activation of NADPH oxidase 
and the generation of peroxynitrite anions, ACE2 
causes vasodilatation, angiogenesis, antioxidative and 
antiapoptotic effects [65].
Both animal studies and clinical studies suggest that 
treatment with the GSH precursor NAC, which is known 
to attenuate the tolerance to nitrates, modifies the function 
of the renin/angiotensin system in vivo, an effect that is 
probably mediated by inhibition of ACE activity  [66]. 
Therefore, by modulating the renin/angiotensin system 
activity, GSH and its precursor thiols are likely to inhibit 
entrance of SARS-CoV-2 into cells.
N-Acetyl-L-cysteine (NAC).  
A promising anti-COVID-19 agent
The thiol NAC easily penetrates cells where it is 
deacetylated to yield L-cysteine (L-Cys), the only 
naturally occurring amino acid that carries a thiol-
containing side chain (sulfhydryl group). Alternatively, 
at least in the blood, NAC acts by freeing in the plasma 
L-Cys that then enters erythrocytes [67]. L-Cys is the rate-
limiting substrate for GSH biosynthesis, which is mainly 
achieved through activation and upregulated production 
of GCL (Fig.  2)  [68]. Therefore, replenishment of 
depleted GSH stores occurs both by GSH recycling and 
by de novo synthesis of this tripeptide (Fig. 2).
The physiological recycling of GSH is increased but 
cannot match its high consumption in COVID-19 lung 
disease. NAC works both per se in the extracellular 
environment and as a substrate and precursor of GSH 
inside cells. Accordingly, all its intracellular effects 
are mediated by GSH replenishment. It is known since 
a long time that rescue of GSH through NAC is a 
treatment strategy for a broad array of different diseases, 
all of which have in common a pathogenetically relevant 
loss of GSH  [69]. It may be possible to discriminate 
whether the effects of NAC are either due to NAC itself 
or to GSH replenishment by comparatively testing its 
unnatural D-isomer that is not a precursor of L-Cys and 
GSH [70].
NAC has been in clinical use since the 1960s as a 
mucolytic agent, usually at the oral dose of 600 mg, due 
to its ability to break the disulfide bonds of mucus and 
to depolymerize mucin. Later on, this drug has been 
proposed or used for the therapy and/or prevention of a 
variety of diseases involving GSH depletion and redox 
status imbalances, such as heart diseases, diabetes, AIDS, 
neurodegenerative diseases, neuropsychiatric disorders, 
and several other conditions, which generally are treated 
with 2 daily oral doses of 600 mg [71-73]. Even higher 
dose regimens (3 daily oral doses of 600 mg) have been 
used for several years for the treatment of idiopathic 
pulmonary fibrosis, whose pathogenesis has been 
ascribed to oxidative agent-mediated alveolar epithelial 
cell injury, accompanied by an abnormal fibroblast 
response  [74]. Note that COVID-19 pneumonia may 
present as an acute exacerbation of idiopathic pulmonary 
fibrosis  [75] and that most of the COVID-19 patients 
undergo postinflammatory pulmonary fibrosis on the 
follow-up CT scan when discharged  [76]. Moreover, 
high-dose intravenous NAC exerts protective effects 
in ARDS [77, 78] that, as previously mentioned, is the 
leading cause of death in COVID-19 patients. ROS play 
a key role in the pathogenesis of the acute lung injury, 
and the alveolar epithelial lining fluid (ELF) of patients 
with ARDS is deficient in GSH [79]. Likewise, GSH is 
depleted in the ELF of patients with sepsis [79]., which 
is another condition associated with COVID-19 [80]. In 
addition, the intravenous administration of NAC at very 
high doses (150 mg/kg b.w.) is used to treat inflammatory 
conditions, such as contrast-induced nephropathy [81], 
and it is in clinical practice as an antidote against 
paracetamol (acetaminophen) overdosage. For this 
reason, NAC is quoted in the WHO Model List of 
Essential Medicines as an antidote in poisonings, being 
almost 100% effective against paracetamol intoxication 
when injected within 8 hours after intake of the drug [81]. 
Furthermore, intravenous NAC may have a role in the 
management of acute liver failure (ALF) attributable to 
administration of remdesivir, a direct-acting nucleoside 
RNA polymerase inhibitor with activity against the novel 
SARS-CoV-2 virus used in the treatment of COVID-19 
pneumonia [82].
Mechanisms of NAC
NAC works via a broad variety of mechanisms, which 
could be exploited for COVID-19 prevention and 
treatment. First of all, as previously reported, thiols 
can hamper penetration of SARS-CoV-2 into cells. 
Another important property is their ability to block 
free radicals and reactive molecules responsible either 
for acute effects or long-term effects. Nucleophilicity 
of thiols is related to the property of sulfhydryl groups 
to react with electrophilic metabolites. An example of 
reactive intermediate is the paracetamol metabolite 
N-acetyl-p-benzoquinone imine (NAPQI) formed via 
cytochrome P450 enzymes, which is bound by GSH 
and excreted in conjugated form. Likewise, NAC and its 
thiol derivatives have the ability to competitively block 
electrophilic derivatives of carcinogens that are capable 
of binding DNA. This may be particularly important 
in the case of smokers, since there is evidence that 
smoking is associated with a negative progression and 
adverse outcomes of COVID-19 [83]. In fact, exposure 
to cigarette smoke increases ROS levels and causes 
a depletion of GSH intracellular concentrations  [84] 
by reacting with nonreducible glutathione-aldehyde 
derivatives  [85] thereby accelerating cigarette smoke-
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induced inflammation and airspace enlargement  [86]. 
NAC has the ability to modulate a large variety of 
smoking-related end-points, due to many mechanisms 
and effects demonstrated in experimental test systems. 
They include NAC nucleophilicity, antioxidant activity, 
modulation of metabolism, effects in mitochondria, 
decrease of the biologically effective dose of carcinogens, 
modulation of DNA repair, inhibition of genotoxicity 
and cell transformation, modulation of gene expression 
and signal transduction pathways, regulation of cell 
survival and apoptosis, antiinflammatory activity, anti-
angiogenetic activity, immunological effects, inhibition 
of progression to malignancy, influence on cell cycle 
progression, inhibition of preneoplastic and neoplastic 
lesions, and inhibition of invasion and metastasis [87]. 
In addition, NAC was shown to modulate several 
biomarkers in a randomized, double-blind, placebo-
controlled, Phase II chemoprevention trial in heavy 
smokers who received NAC tablets (600 mg) twice daily 
for 6 months [88].
The key mechanisms shared by NAC, L-Cys and GSH 
are related to their antioxidant activity, which is mainly 
due to a potent ability to scavenge ROS (Fig.  2), and 
especially hypochlorous acid (HOCl) and •OH, and 
additionally hydrogen peroxide  [89]. The SH-groups 
within the NAC molecule can also scavenge several 
RNS that play a role in the oxidation of lipids, proteins, 
and DNA [90]. 
The antioxidant effects are interconnected with 
antiinflammatory effects, which is crucial for COVID-19 
control [49]. First of all, oxidative stress is linked with 
inflammation via two parallel biochemical channels that 
are modulated in opposite direction by NAC (Fig. 3). The 
first one involves inhibition by NAC of the ROS-mediated 
activation of NF-κB and consequently the hindrance of 
biochemical pathways upregulating pro-inflammatory 
genes [71] involved in COVID-19 pathogenesis, such as 
interleukins (IL-1β, IL-6, IL-8), prostaglandins (PGE-
2), cyclooxygenases (COX-2), tumor necrosis factor 
(TNF-α), matrix metalloproteinases (MMP-3, MMP-4), 
and intercellular adhesion molecule (ICAM-1). NAC also 
inhibits NF-κB translocation to the cellular nucleus and 
phosphorylation of MAPK p38 (p38 mitogen-activated 
protein kinase) by reducing the intracellular hydrogen 
peroxide concentration and by restoring the intracellular 
total thiol contents [91]. On the other hand, NAC further 
enhances the stimulation of Nrf2 by oxidative stress 
[92]. Nrf2 downregulates inflammation by favouring the 
ARE-mediated transcription of phase II enzyme genes. 
These include endogenous antioxidant enzymes such as 
heme oxygenase 1 (HO-1), NAD(P)H dehydrogenase 
[quinone] 1 (NQO-1) and additionally GCL  [93]. It 
is noteworthy that the heme-HO-1 system has been 
proposed as a target to prevent severe complications 
following SARS-CoV-2 infection [94]. 
Besides acting as antioxidants by scavenging ROS, NAC 
and GSH elicit antioxidant and antiinflammatory effects 
via other mechanisms that may bear relevance for the 
control of COVID-19 and associated co-morbidities. 
For instance, NAC can exert antioxidant activity via 
p53 mediated apoptosis  [95]. In the cardiovascular 
domain, NAC is well known to interact with nitric oxide 
by potentiating its vasodilator and antiaggregatory 
effects [96]. Moreover, NAC inhibits the ROS-producing 
vascular NAD(P)H oxidases, which bears relevance in 
the prevention of hypertension and atherosclerosis [97]. 
NAC has also been proposed with the goal of preserving 
endothelial function and limiting microthrombosis in 
severe forms of COVID-19  [98]. Of particular interest 
in the framework of the COVID-19 clinical picture 
is inhibition of epidermal growth factor receptor 
(EGFR), a tyrosine kinase involved in inflammation, 
which also results in a decreased inactivation of α1-
antitrypsin that, together with oxidative stress, plays 
an important role in the pathogenesis of COPD and 
its exacerbations  [99,  100]. In addition, NAC is a 
hydrogen sulfide donor, because L-Cys, derived by NAC 
catabolism, is the substrate for this vasodilator, anti-
inflammatory and readily diffusible compound  [101], 
which is a pleiotropic mediator having effects on many 
elements in the inflammatory cascade and promoting the 
resolution of inflammation and injury [102].
Conclusions
Oxidative stress represents a major mechanism in the 
pathogenesis not only of chronic degenerative diseases 
but also of infectious diseases, also including viral 
respiratory diseases. Oxidation, inflammation and 
immune response impairment are strictly interconnected 
and are key determinants in COVID-19. Various 
antioxidants have been proposed as anti-SARS-CoV-2 
agents. One of the most promising drugs is NAC, a 
precursor of GSH, both because the redox environment 
of the ACE2 receptor of SARS-CoV-2 spikes is regulated 
by the thiol-disulfide balance in the extracellular region 
Fig. 3. NAC and GSH trigger two parallel channels that attenu-
ate inflammation either by inhibiting NFκB-dependent pro-in-
flammatory genes and/or by stimulating Nrf2-dependent anti-
inflammatory genes (see Text for details).
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and because replenishment of depleted GSH stores by 
NAC exerts formidable antioxidant and antiinflammatory 
effects. These effects are potentially suitable to control 
the cytokine storm that is characteristic of COVID-19. 
Due to their pleiotropic mechanisms, both NAC and 
GSH have been evaluated or are under scrutiny for a 
variety of end-points in a large number of clinical trials 
(162 studies for GSH and 714 studies for NAC)  [57]. 
We  [49] and several other authors  [43,  103-115] have 
proposed the use of NAC in the prevention and/or the 
treatment of COVID-19. Due to its low toxicity profiles, 
the 60 year-experience of clinical use and the fact that 
NAC is approved by FDA under various formulations 
and is popular as a health supplement, this drug may be 
repurposed as an anti-COVID-19 agent.
In particular, two strategies can be envisaged. The first 
one is the oral administration of NAC, at the dose of 
600 mg twice per day, in order to decrease the risk of 
developing COVID-19 and to attenuate its severity, 
especially during epidemic periods and in high 
risk individuals because of age and/or concomitant 
pathological conditions or because they have been 
in contact with infected SARS-CoV-2 carriers. 
Interestingly, having previously demonstrated that 
this protocol is effective in lowering the incidence and 
severity of influenza and influenza-like illnesses  [8], 
the hypothesis that NAC administration may confer a 
broad spectrum protection against different respiratory 
viral diseases is mechanistically sound. It is also 
noteworthy that oral NAC (600 mg/twice daily) was safe 
and effective to prevent and delay ventilator-associated 
pneumonia, and improved its complete recovery rate 
in a selected, high-risk ICU population  [116]. At the 
same NAC dose, a cross sectional study evaluating 
164 COVID-19 patients in Kolkata (India) found that 
moderate-severe patients who received NAC along 
with standard therapy had a variety of benefits from the 
clinical standpoint [117].
The second perspective, in case of manifest COVID-19 
forms, is to use NAC as an adjuvant therapy, possibly in 
association with other drugs, at the high intravenous doses 
that are commonly used as an antidote against paracetamol 
intoxication. It is noteworthy that paracetamol, which is 
the preferred drug for the symptomatic and domiciliary 
management of the early stages of COVID-19, may 
cause GSH depletion, especially in people at higher 
COVID-19 risk, thereby increasing further the risk of 
developing severe COVID-19 forms [118]. Accordingly, 
the preferential use of paracetamol in COVID-19 as a 
safer alternative to nonsteroidal antiinflammatory drugs 
(NSAIDs) should be carefully reconsidered  [119] and 
it would be important to further investigate whether 
NAC supplementation should be adopted, irrespective 
of COVID-19, in case of prolonged administration of 
high doses of this antipyretic and analgesic compound 
[118]. A case of severe COVID-19 infection treated with 
hydroxychloroquine in a patient deficient in glucose 
6-phosphate dehydrogenase (G6PD), which facilitates 
human coronavirus infection due to GSH depletion, 
had benefit from the intravenous administration 
of NAC  [43]. On the other hand, a double-blind, 
randomized, placebo-controlled trial enrolling 
135 patients with severe COVID-19 (confirmed or 
suspected), conducted in São Paulo, Brazil, did not 
show any benefit from the intravenous injection of 21 
g NAC (approximately 300  mg/kg) for 20  hours, at 
least in terms of need for endotracheal intubation and 
mechanical ventilation [120].
Several clinical trials evaluating the efficacy and safety of NAC 
treatment in COVID-19 are now in progress in various countries, 
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